Anıl Aktaş Samur

18PUBLICATIONS
103CO-AUTHORS
Medical infection agents (incl. prions)Molecular targetsAutoimmunityMedical mycologyCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 04, 2026
DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

|Jul 29, 2026
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

|Jul 15, 2026
The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

|Jun 04, 2026
PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

|Dec 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Anil Aktas Samur, Jill Corre, Srikanth Talluri

|May 22, 2025
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano

Pageof 3

Frequent Collaborators

7 joint publications

Jill Corre

6 joint publications

Eugenio Morelli

5 joint publications

Masood Shammas

5 joint publications

Mariateresa Fulciniti